SCHEMBL20115467

SCHEMBL20115467

CCNC(=S)N/N=C/c1ccc(-c2ccc(OC)cc2)o1

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 8/20 0.78
KDM4E B2RXH2 5/20 0.78
ALDH1A1 P00352 4/20 0.78
MEN1 O00255 3/20 0.78
KMT2A Q03164 3/20 0.78
MAPK1 P28482 1/20 0.78
PHGDH O43175 9/20 0.77
LMNA P02545 1/20 0.74
HPGD P15428 1/20 0.74
ALOX12 P18054 1/20 0.74
NPC1 O15118 3/20 0.67
RAB9A P51151 2/20 0.67
CRHBP P24387 1/20 0.57
CRHR2 Q13324 1/20 0.57
TDP1 Q9NUW8 2/20 0.56
HTT P42858 1/20 0.56
L3MBTL1 Q9Y468 2/20 0.53
POLB P06746 1/20 0.53
HSP90AA1 P07900 1/20 0.53
PKM P14618 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20115431 0.87 PHGDH (1.00) MAPTKDM4EALDH1A1MEN1KMT2A
SCHEMBL20115489 0.87 PHGDH (0.82) MAPTKDM4EALDH1A1MEN1KMT2A
SCHEMBL21292670 0.86 PHGDH (0.80) MAPTKDM4EALDH1A1MEN1KMT2A
SCHEMBL20115497 0.86 PHGDH (0.80) MAPTKDM4EALDH1A1MEN1KMT2A
SCHEMBL20115491 0.86 PHGDH (0.80) MAPTKDM4EALDH1A1MEN1KMT2A
SCHEMBL21292759 0.85 ALDH1A1 (1.00) MAPTKDM4EALDH1A1MEN1KMT2A
SCHEMBL20115430 0.85 PHGDH (0.80) MAPTKDM4EALDH1A1MEN1KMT2A
SCHEMBL21292823 0.84 PHGDH (0.77) MAPTKDM4EALDH1A1MEN1KMT2A
SCHEMBL4336149 0.83 MAPT (0.74) MAPTKDM4EALDH1A1MEN1KMT2A
SCHEMBL4336150 0.83 MAPT (0.74) MAPTKDM4EALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10722489-B2 D-3-phosphoglycerate dehydrogenase allosteric inhibitor and use thereof PEKING UNIVERSITY (CN) 2020-07-28 US disclosed
US-10722489-B2 D-3-phosphoglycerate dehydrogenase allosteric inhibitor and use thereof PEKING UNIVERSITY (CN) 2020-07-28 US disclosed
US-20200054593-A1 D-3-PHOSPHOGLYCERATE DEHYDROGENASE ALLOSTERIC INHIBITOR AND USE THEREOF UNIV BEIJING (CN) 2020-02-20 US disclosed
US-20200054593-A1 D-3-PHOSPHOGLYCERATE DEHYDROGENASE ALLOSTERIC INHIBITOR AND USE THEREOF UNIV BEIJING (CN) 2020-02-20 US disclosed
CN-106562951-B Furan D-3-phosphoglycerate dehydrogenase allosteric inhibitor and its application 北京大学 2020-02-11 CN disclosed
US-20190262303-A1 D-3-PHOSPHOGLYCERATE DEHYDROGENASE ALLOSTERIC INHIBITOR AND USE THEREOF UNIV BEIJING (CN) 2019-08-29 US disclosed
US-20190262303-A1 D-3-PHOSPHOGLYCERATE DEHYDROGENASE ALLOSTERIC INHIBITOR AND USE THEREOF UNIV BEIJING (CN) 2019-08-29 US disclosed
WO-2018076537-A1 D-3-PHOSPHOGLYCERATE DEHYDROGENASE ALLOSTERIC INHIBITOR AND USE THEREOF 北京大学 2018-05-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10722489-B2 D-3-phosphoglycerate dehydrogenase allosteric inhibitor and use thereof MDH2, MDH1, DLD MAPT 3785/4885KDM4E 1863/4885ALDH1A1 447/4885
US-20200054593-A1 D-3-PHOSPHOGLYCERATE DEHYDROGENASE ALLOSTERIC INHIBITOR AND USE THEREOF MDH2, MDH1, DLD MAPT 3785/4885KDM4E 1863/4885ALDH1A1 447/4885
US-20190262303-A1 D-3-PHOSPHOGLYCERATE DEHYDROGENASE ALLOSTERIC INHIBITOR AND USE THEREOF MDH2, MDH1, DLD MAPT 3785/4885KDM4E 1863/4885ALDH1A1 447/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.